Notice Pursuant to the National Cooperative Research and Production Act of 1993-Subcutaneous Drug Development & Delivery Consortium, Inc., 104209-104210 [2024-30418]
Download as PDF
<![CDATA[
ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 245 / Friday, December 20, 2024 / Notices
Wilmington, DE; Serimmune, Goleta,
CA; UNITED KINGDOM HEALTH
SECURITY AGENCY (UKHSA),
Salisbury, UNITED KINGDOM;
University of Connecticut, Farmington,
CT; VGXI, Inc., Conroe, TX; ABSS
Solutions, Inc., Upper Marlboro, MD;
BiosYnth SRL, Milan, ITALY; Idevax,
Wijnegem, BELGIUM; IntegerBio, Inc.,
Gaithersburg, MD; Phoreus
Biotechnology, Inc., Olathe, KS;
PrecNA, LLC, North Potomac, MD;
Sepragen Corp., Union City, CA; Trellis
Bioscience, Inc., Redwood City, CA; AB
Validation, Inc., Quebec, CANADA;
AuraVax Therapeutics, Inc., Houston,
TX; CuriRx, Inc., Wilmington, MA; IMA
Evaluations, LLC, dba IMA Clinical
Research, Tarrytown, NY; MustardSeed
PMO, West Chester, PA; Symbiosis.io,
LLC, Smyrna, GA; Tornado
Therapeutics, Boston, MA; Amneal
Pharmaceuticals of New York, LLC,
Brookhaven, NY; Blue Spark
Technologies, Inc., Westlake, OH;
Inhalon Biopharma, Inc., Morrisville,
NC; Intelligene, Inc., Taipei, TAIWAN;
Rocket Science Health US Corp., Seattle,
WA; Rutgers, The State University of
New Jersey, Piscataway, NJ; The
Administrators of the Tulane
Educational Fund, New Orleans, LA;
Verisim Life, Inc., San Francisco, CA;
Arcturus Therapeutics Holdings, Inc.,
San Diego, CA; Blu Zone Bioscience &
Supply Chain Solutions, LLC, Frederick,
MD; Elligo Health Research, Inc.,
Austin, TX; Guide Biomedical
Solutions, LLC, Media, PA; Integral
Molecular, Philadelphia, PA; Komo
Biosciences, Inc., Newton, MA; P95, BV,
Leuven, BELGIUM; Southwest Research
Institute, San Antonio, TX; Statistics &
Data Corp., Tempe, AZ; Stoic Bio, Inc.,
San Diego, CA; Valaria Technical
Consultants, LLC, Westminster, MD;
Vaxine Pty, Ltd., Marion, AUSTRALIA;
Zeteo Biomedical, LLC, Austin, TX;
Concept to Market, LLC, Monrovia, MD;
DSBio Consulting, LLC, Annapolis, MD;
Deimos Biosciences, San Francisco, CA;
GMED North America, Inc., Rockville,
MD; InvisiShield Technologies, Ltd.,
Emeryville, CA; MigVax, Ltd., Kiryat
Shmona, ISRAEL; Polaris Alpha
Advanced Systems, Inc.,
Fredericksburg, VA; Pop Test Oncology,
LLC, Cliffside Park, NJ; Sapphiros,
Boston, MA; Articulate Labs, Inc.,
Dallas, TX; Empatica, Inc., Cambridge,
MA; LifeMine Therapeutics, Inc.,
Cambridge, MA; Luminous
Therapeutics Corp., Columbia, MD;
Nabla Bio, Inc., Cambridge, MA;
Qoolabs, Inc., Carlsbad, CA; Rapid
Novor, Inc., Kitchener, CANADA;
Scorpius BioManufacturing, San
Antonio, TX; Sunflower Therapeutics
VerDate Sep<11>2014
20:12 Dec 19, 2024
Jkt 265001
PBC, Medford, MA; GreenRoads
Diagnostics, Inc., San Diego, CA; Logical
Images, dba ‘‘VisualDx’’, Rochester, NY;
Mirai Biosciences, Cambridge, MA; The
Scripps Research Institute, La Jolla, CA;
AmplifyBio, LLC, West Jefferson, OH;
Andelyn Biosciences, Inc., Columbus,
OH; Binary Pharmaceuticals, LLC, Hot
Springs, AR; BioCina PTY, Ltd., West
Torrens, AUSTRALIA; Cypress
Biologics, LLC, Portland, OR; Fermeate,
Inc., San Francisco, CA; HMH Hospitals
Corp, dba CDI, Nutley, NJ; Meso Scale
Diagnostics, LLC, Rockville, MD;
Systems & Technology Research, LLC,
Woburn, MA; Telesis Bio, San Diego,
CA; Thermo Fisher, South San
Francisco, CA; University of
Massachusetts Lowell, Lowell, MA;
ViQi, Inc., Santa Barbara, CA;
DemeTech Corp., Miami, FL; INFEX
Therapeutics, Alderley Edge, UNITED
KINGDOM; Mercury Bio, Inc., Santa Fe,
NM; Phageolytix, Inc., Jacksonville, FL;
Phenom Pharmaceuticals, LLC, Miami
Beach, FL; RIBOPRO BV, Oss,
NETHERLANDS; RNhale GmbH,
Munich, GERMANY; The University of
Chicago Medicine, Chicago, IL; Bioblue
CMC/Manufacturing Consulting, LLC,
San Diego, CA; Oligo Foundry, Inc., San
Diego, CA; PNUVAX, Inc., Wilmington,
DE; Prosoft Software, Inc., dba Prosoft
Clinical, Chesterbrook, PA; Simon
Williams Pharma Consulting (SWPC),
LLC, Gibbsboro, NJ; Dillico, Meylan,
FRANCE; INFINIFLUIDICS,
Philadelphia, PA; Primrose Bio, Inc.,
San Diego, CA; SIMETRI, Inc., Winter
Park, FL; The Trustees of the University
of Pennsylvania, Philadelphia, PA; and
WCG, Princeton, NJ, have been added as
parties to this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and RRPV intends
to file additional written notifications
disclosing all changes in membership.
On January 5, 2024, RRPV filed its
original notification pursuant to section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to section 6(b) of the
Act on April 16, 2024 (89 FR 26928).
The last notification was filed with
the Department on July 11, 2024. The
Department of Justice published a notice
in the Federal Register pursuant to
section 6(b) of the Act on October 11,
2024 (89 FR 82631).
Suzanne Morris,
Deputy Director Civil Enforcement
Operations, Antitrust Division.
[FR Doc. 2024–30403 Filed 12–19–24; 8:45 am]
BILLING CODE P
PO 00000
Frm 00138
Fmt 4703
Sfmt 4703
104209
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—UHD Alliance
Notice is hereby given that, on
October 8, 2024, pursuant to section 6(a)
of the National Cooperative Research
and Production Act of 1993, 15 U.S.C.
4301 et seq. (‘‘the Act’’), UHD Alliance,
Inc. (‘‘UHD Alliance’’) filed written
notifications simultaneously with the
Attorney General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, TTE Corporation,
Shenzhen, PEOPLE’S REPUBLIC OF
CHINA has been added as a party to this
venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and UHD Alliance
intends to file additional written
notifications disclosing all changes in
membership.
On June 17, 2015, UHD Alliance filed
its original notification pursuant to
section 6(a) of the Act. The Department
of Justice published a notice in the
Federal Register pursuant to section
6(b) of the Act on July 17, 2015 (80 FR
42537).
The last notification was filed with
the Department on July 8, 2024. A
notice was published in the Federal
Register pursuant to section 6(b) of the
Act on September 26, 2024 (89 FR
78904).
Suzanne Morris,
Deputy Director Civil Enforcement
Operations, Antitrust Division.
[FR Doc. 2024–30412 Filed 12–19–24; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Subcutaneous Drug
Development & Delivery Consortium,
Inc.
Notice is hereby given that, on
October 4, 2024, pursuant to section 6(a)
of the National Cooperative Research
and Production Act of 1993, 15 U.S.C.
4301 et seq. (‘‘the Act’’), Subcutaneous
Drug Development & Delivery
E:\FR\FM\20DEN1.SGM
20DEN1
104210
Federal Register / Vol. 89, No. 245 / Friday, December 20, 2024 / Notices
Consortium, Inc. (‘‘Subcutaneous Drug
Development & Delivery Consortium,
Inc.’’) has filed written notifications
simultaneously with the Attorney
General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, Janssen Research &
Development, LLC, Malver, PA; Novo
Nordisk, Bagsvaerd, DENMARK; and
Ypsomed AG, Burgdorf,
SWITZERLAND have been added as
parties to this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and Subcutaneous
Drug Development & Delivery
Consortium, Inc. intends to file
additional written notifications
disclosing all changes in membership.
On October 26, 2020, Subcutaneous
Drug Development & Delivery
Consortium, Inc. filed its original
notification pursuant to section 6(a) of
the Act. The Department of Justice
published a notice in the Federal
Register pursuant to section 6(b) of the
Act on December 3, 2020 (85 FR 78148).
The last notification was filed with
the Department on April 25, 2024. A
notice was published in the Federal
Register pursuant to section 6(b) of the
Act on September 12, 2024 (89 FR
74288).
Suzanne Morris,
Deputy Director Civil Enforcement
Operations, Antitrust Division.
[FR Doc. 2024–30418 Filed 12–19–24; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Antitrust Division
ddrumheller on DSK120RN23PROD with NOTICES1
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Senior Healthcare
Innovation Consortium
Notice is hereby given that, on
October 2, 2024 pursuant to section 6(a)
of the National Cooperative Research
and Production Act of 1993, 15 U.S.C.
4301 et seq. (‘‘the Act’’), Senior
Healthcare Innovation Consortium
(SHIC) has filed written notifications
simultaneously with the Attorney
General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
VerDate Sep<11>2014
20:12 Dec 19, 2024
Jkt 265001
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, AIVOT Robotics, Inc.,
Seattle, WA; Living Solutions, Afton,
WY; Thrive360AI, San Francisco, CA;
and Tornado Therapeutics, Boston, MA,
have been added as parties to this
venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and SHIC intends
to file additional written notifications
disclosing all changes in membership.
On November 2, 2022, SHIC filed its
original notification pursuant to section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to section 6(b) of the
Act on November 23, 2022 (87 FR
71677).
The last notification was filed with
the Department on July 10, 2024. A
notice was published in the Federal
Register pursuant to section 6(b) of the
Act on September 26, 2024 (89 FR
78902).
Suzanne Morris,
Deputy Director Civil Enforcement
Operations, Antitrust Division.
[FR Doc. 2024–30405 Filed 12–19–24; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Medical Technology
Enterprise Consortium
Notice is hereby given that, on
October 7, 2024, pursuant to section 6(a)
of the National Cooperative Research
and Production Act of 1993, 15 U.S.C.
4301 et seq. (‘‘the Act’’), Medical
Technology Enterprise Consortium
(‘‘MTEC’’) has filed written notifications
simultaneously with the Attorney
General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, Artery Studios, Inc.,
Toronto, CANADA; Astek Diagnostics,
Inc., Halethorpe, MD; BBC
Entrepreneurial Training and
Consulting, LLC, Chelsea, MI; Bluestaq,
LLC, Colorado Springs, CO; Carrtech
Corp., Dickerson, MD; Concept Plus,
LLC, Fairfax, VA; Crescel, LLC, Miami
Beach, FL; Culmen International, LLC,
Alexandria, VA; DeployX Services, Inc.,
PO 00000
Frm 00139
Fmt 4703
Sfmt 4703
McLean, VA; Digital For Mental Health,
Paris, FRANCE; Emvision Medical
Devices, Ltd., Macquarie Park,
AUSTRALIA; Galapagos Federal
Systems, LLC, Kihei, HI; GoDx, Inc.,
Madison, WI; Government Acquisitions,
Inc., Cincinnati, OH; IntelliDyne, LLC,
Vienna, VA; IRegained, Inc., Sudbury,
CANADA; Northeastern University,
Boston, MA; Nytricx, Inc., Athens, GA;
Omnix Medical, Jerusalem, ISRAEL;
Perfusio Corp., Greenville, NC;
Protondx, Ltd., London, UNITED
KINGDOM; PSC Biotech Corp., Pomona,
CA; Razom, Inc., New York, NY; ReliOx
Corp., Jacksonville, FL; SeaStar Medical,
Inc., Denver, CO; SPEAR Human
Performance, Inc., Tallahassee, FL;
SPOC Proteomics, Inc., Scottsdale, AZ;
TechWerks, LLC, Arlington Heights, IL;
The Neutrino Donut, LLC, Culver City,
CA; Unify Medical, Cleveland, OH;
University of South Carolina, Columbia,
SC; Wearabledose, Inc., Bowie, MD;
Zeteo Tech, Inc., Sykesville, MD; and
ZuluCare, LLC, Bethpage, NY, have
been added as parties to this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and MTEC
intends to file additional written
notifications disclosing all changes in
membership.
On May 9, 2014, MTEC filed its
original notification pursuant to section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to section 6(b) of the
Act on June 9, 2014 (79 FR 32999).
The last notification was filed with
the Department on June 28, 2024. A
notice was published in the Federal
Register pursuant to section 6(b) of the
Act on September 16, 2024 (89 FR
75566).
Suzanne Morris,
Deputy Director Civil Enforcement
Operations, Antitrust Division.
[FR Doc. 2024–30411 Filed 12–19–24; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Naval Surface
Technology & Innovation Consortium
Notice is hereby given that, on
October 10, 2024, pursuant to section
6(a) of the National Cooperative
Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (‘‘the Act’’), Naval
Surface Technology & Innovation
E:\FR\FM\20DEN1.SGM
20DEN1
]]>Agencies
[Federal Register Volume 89, Number 245 (Friday, December 20, 2024)]
[Notices]
[Pages 104209-104210]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-30418]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Subcutaneous Drug Development & Delivery
Consortium, Inc.
Notice is hereby given that, on October 4, 2024, pursuant to
section 6(a) of the National Cooperative Research and Production Act of
1993, 15 U.S.C. 4301 et seq. (``the Act''), Subcutaneous Drug
Development & Delivery
[[Page 104210]]
Consortium, Inc. (``Subcutaneous Drug Development & Delivery
Consortium, Inc.'') has filed written notifications simultaneously with
the Attorney General and the Federal Trade Commission disclosing
changes in its membership. The notifications were filed for the purpose
of extending the Act's provisions limiting the recovery of antitrust
plaintiffs to actual damages under specified circumstances.
Specifically, Janssen Research & Development, LLC, Malver, PA; Novo
Nordisk, Bagsvaerd, DENMARK; and Ypsomed AG, Burgdorf, SWITZERLAND have
been added as parties to this venture.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research project remains open, and Subcutaneous Drug Development &
Delivery Consortium, Inc. intends to file additional written
notifications disclosing all changes in membership.
On October 26, 2020, Subcutaneous Drug Development & Delivery
Consortium, Inc. filed its original notification pursuant to section
6(a) of the Act. The Department of Justice published a notice in the
Federal Register pursuant to section 6(b) of the Act on December 3,
2020 (85 FR 78148).
The last notification was filed with the Department on April 25,
2024. A notice was published in the Federal Register pursuant to
section 6(b) of the Act on September 12, 2024 (89 FR 74288).
Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2024-30418 Filed 12-19-24; 8:45 am]
BILLING CODE P
